Efficacy
The long term results of the CROSS study confirm the initially reportedr survival benefit for neoadjuvant chemoradiation therapy plus surgery compared with surgery alone.r
After a median follow-up of 84.1 months for surviving patients, the median overall survival for the neoadjuvant chemoradiation therapy plus surgery group was 48.6 months (95% CI, 32·1 - 65·1) compared to 24·0 months (95% CI,14·2 - 33·7) in the surgery alone group (HR 0·68 [95% CI, 0·53 - 0·88]; log-rank p=0·003).r
Kaplan-Meier plot of estimated overall survival by treatment group
© Lancet Oncol 2015
For patients with squamous cell carcinoma (SCC) the median overall survival was significantly longer in the neoadjuvant chemoradiation therapy plus surgery group (81.6 months (95% CI, 47.2 - 116.0)) compared to 21·1 months (15·4 - 26·7) in the surgery alone group (HR 0·48 [95% CI 0·28 - 0·83]; log rank p = 0.008).r
Patients with adenocarcinoma (AC) had a median overall survival of 43·2 months (24·9 - 61·4) in the neoadjuvant chemoradiation therapy plus surgery group compared to 27·1 months (13·0 - 41·2) in the surgery alone group (HR 0·73 [95% CI 0·55 - 0·98]; log rank p = 0.038).r
Kaplan-Meier plot of estimated overall survival by treatment group and histological tumour type
© Lancet Oncol 2015
Hazard ratios for all-cause mortality, according to subgroup characteristics
© Lancet Oncol 2015